Neurobo Pharmaceuticals Inc
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has com… Read more
Market Cap & Net Worth: Neurobo Pharmaceuticals Inc (NRBO)
Neurobo Pharmaceuticals Inc (NASDAQ:NRBO) has a market capitalization of $16.54 Million ($16.54 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #32050 globally and #10528 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurobo Pharmaceuticals Inc's stock price $1.92 by its total outstanding shares 8616010 (8.62 Million).
Neurobo Pharmaceuticals Inc Market Cap History: 2016 to 2025
Neurobo Pharmaceuticals Inc's market capitalization history from 2016 to 2025. Data shows change from $405.30 Billion to $16.54 Million (-70.21% CAGR).
Index Memberships
Neurobo Pharmaceuticals Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2606 of 3165 |
Weight: Neurobo Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neurobo Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neurobo Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4550.48x
Neurobo Pharmaceuticals Inc's market cap is 4550.48 times its annual revenue
1728.56x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $31.85 Million | $7.00K | -$12.47 Million | 4550.48x | N/A |
Competitor Companies of NRBO by Market Capitalization
Companies near Neurobo Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Neurobo Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Neurobo Pharmaceuticals Inc Historical Marketcap From 2016 to 2025
Between 2016 and today, Neurobo Pharmaceuticals Inc's market cap moved from $405.30 Billion to $ 16.54 Million, with a yearly change of -70.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $16.54 Million | +9.09% |
| 2024 | $15.16 Million | -52.39% |
| 2023 | $31.85 Million | -35.64% |
| 2022 | $49.49 Million | -98.04% |
| 2021 | $2.52 Billion | -76.76% |
| 2020 | $10.86 Billion | -40.00% |
| 2019 | $18.09 Billion | -56.79% |
| 2018 | $41.87 Billion | -89.80% |
| 2017 | $410.73 Billion | +1.34% |
| 2016 | $405.30 Billion | -- |
End of Day Market Cap According to Different Sources
On Jan 23rd, 2026 the market cap of Neurobo Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.54 Million USD |
| MoneyControl | $16.54 Million USD |
| MarketWatch | $16.54 Million USD |
| marketcap.company | $16.54 Million USD |
| Reuters | $16.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.